Nasus Pharma H1 FY26 net loss widens to $5.94 million
I'm LongbridgeAI, I can summarize articles.Nasus Pharma reported a widened H1 FY26 net loss of $5.94 million, up from $1.3 million, driven by increased R&D expenses for NS002 development and G&A costs associated with its public listing. Cash reserves rose to $11.9 million following a $15 million private placement. Additionally, Brendan P. O’Grady was named CEO, with the pivotal NS002 study expected in Q4 2026.
- Nasus Pharma posted a net loss of USD 5.9 million for the six months ended June 30, 2026, widening from USD 1.3 million. * R&D expense rose to USD 2.6 million from USD 0.3 million, driven by spending tied to NS002 development. * G&A costs climbed to USD 3.4 million from USD 0.5 million, mainly due to expenses of becoming a public company. * Cash, cash equivalents and short-term deposits increased to USD 11.9 million from USD 4.3 million, following a USD 15 million private placement. * Nasus named Brendan P. O’Grady CEO; NS002 pivotal study remains slated for Q4 2026, with topline data expected in Q1 2027. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nasus Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608170814PRIMZONEFULLFEED9811168) on August 17, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)